MedTrace Logo

Real-World Immuno-Radiotherapy for Advanced NSCLC

NCT06747026 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 338

Last updated 2024-12-24

No results posted yet for this study

Summary

The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy. The objective of this study is to confirm the survival benefits of iRT in advanced NSCLC and to identify the optimal combination strategy for its use.

Conditions

  • Lung Cancer Non-Small Cell Cancer (NSCLC)

Interventions

DRUG

initial Sequential iRT

For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT. For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days.

DRUG

initial Concurrent iRT

For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT. For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT.

DRUG

RT with maintenance of ICI

For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.

DRUG

RT after discontinuation of ICI

For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.

Sponsors & Collaborators

  • Fengming Kong

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06747026 on ClinicalTrials.gov